|  | Univariate | Multivariate** | ||
---|---|---|---|---|---|
 |  | sHR (95% CI) | p-value | sHR (95% CI) | p-value |
Age | <  65 | – | – | – | – |
≥ 65 | 1.38 (1.11–1.71) | 0.004 | 1.40 (1.11–1.76) | 0.005 | |
Gender | Male | – | – | – | – |
Female | 0.68 (0.53–0.87) | 0.002 | 0.73 (0.57–0.94) | 0.016 | |
Metastasis |  | 1.58 (1.26–1.98) | < 0.0001 | 1.38 (1.08–1.78) | 0.011 |
PE |  | 2.88 (1.83–4.52) | < 0.0001 | 2.90 (1.85–4.54) | < 0.0001 |
DVT |  | 1.53 (0.96–2.43) | 0.074 |  |  |
Anticoagulant therapy |  | 1.91 (1.41–2.59) | < 0.0001 | 1.77 (1.30–2.43) | 0.0003 |
Antiplatelet therapy |  | 1.36 (1.09–1.71) | 0.007 | 1.27 (1.01–1.60) | 0.044 |
NSAID therapy |  | 0.71 (0.49–1.03) | 0.075 |  |  |
Lung cancer surgery |  | 1.79 (1.33–2.42) | 0.0001 | 2.54 (1.88–3.45) | < 0.0001 |
Other surgery |  | 1.68 (1.26–2.23) | 0.0004 | 1.50 (1.11–2.02) | 0.009 |
Chemotherapy |  | 1.66 (1.30–2.13) | < 0.0001 | 1.54 (1.19–2.00) | 0.001 |
Bevacizumab |  | 1.04 (0.49–2.21) | 0.919 |  |  |
Oral targeted therapy |  | 0.97 (0.47–1.97) | 0.925 |  |  |
Radiotherapy |  | 1.80 (1.34–2.41) | 0.0001 | 1.71 (1.25–2.34) | 0.001 |